Hep C treatment halved, cure rate doubled

Professor Ed Gane, deputy director of the New Zealand Liver Transplant Institute, said new oral antivirals such as sofosbuvir (Gilead) and simeprevir (Janssen) also have fewer side effects and are safe to use in patients co-infected with HIV and those who have had a liver transplant.

In clinical trials, adding simeprevir to the current treatment of interferon plus ribavirin in patients with genotype 1 doubled cure rates from 40% to 80% and treatment time halved from 48 weeks to 24. Similarly, using sofosbuvir